BlueWhale Bio
BlueWhale Bio is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania that develops Synecta cell-derived nanoparticles (CDNPs) for T-cell activation and expansion in CAR-T cell therapy manufacturing. It sells research-use reagents directly to cell therapy developers, with GMP-grade scale-up supported through an Avantor partnership.
- Company typePrivate
- Founded2023
- HeadquartersPhiladelphia, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BlueWhale Bio does
BlueWhale Bio, Inc. is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania in September 2023 that develops and sells cell-derived nanoparticle (CDNP) reagents under the Synecta platform for immune cell activation and expansion in cell and gene therapy manufacturing. The company's core products — Synecta T1, Synecta T2, and Synecta Modular — are engineered vesicles produced from mammalian cell lines that present defined combinations of stimulatory signals (e.g., OKT3 scFV), co-stimulatory ligands (CD86, 4-1BBL), and membrane-bound cytokines (IL-15RA/IL-15, IL-7) to drive T-cell activation in CAR-T workflows. The technology is licensed from co-founders Carl June and James Riley of Penn's Perelman School of Medicine, both globally recognized immunotherapy pioneers. Synecta is positioned to replace conventional bead-based activation methods, enabling Day 0 lentiviral transduction, eliminating bead-removal steps, and shortening manufacturing cycles (claims include a 3-day process versus longer conventional approaches).
The company monetizes primarily through direct sales of research-use CDNPs to cell therapy developers and academic medical centers, with quote-based pricing (net 30 terms) per the website Terms and Conditions. Go-to-market is enterprise field sales supplemented by conference presence (Cell & Gene Meeting on the Mesa, ISCT, AACR, IO360, SITC) and webinars. A strategic partnership with Avantor (announced October 2025) extends distribution into GMP-grade manufacturing scale for commercial cell therapy production. The company has secured an FDA Advanced Manufacturing Technology (AMT) designation (November 2025) and an accepted Drug Master File for Synecta T1, and achieved first-patient dosing in a University of Pennsylvania clinical trial (NCT04684563) in September 2025. As of the latest data, BlueWhale Bio had raised $18 million in seed financing led by Danaher Ventures with participation from Novalis LifeSciences and Marshall Wace, and disclosed a $15 million exempt securities offering (with $5 million sold) in 2025, while operating with 11-50 employees.
BlueWhale Bio firmographics
Firmographics- Name
- BlueWhale Bio
- Legal name
- BlueWhale Bio, Inc.
- Website
- https://bluewhale.bio
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BlueWhale Bio is a Philadelphia-based biotechnology company spun out of the University of Pennsylvania that develops Synecta cell-derived nanoparticles (CDNPs) for T-cell activation and expansion in CAR-T cell therapy manufacturing. It sells research-use reagents directly to cell therapy developers, with GMP-grade scale-up supported through an Avantor partnership.
- Ownership category
- akta.pro rank
BlueWhale Bio industry classification
Industry- Product category
- Cell Therapy Manufacturing Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
- akta.pro secondary industries
- Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)
Keywords
Where BlueWhale Bio is headquartered
LocationHeadquarters
- HQ city
- Philadelphia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BlueWhale Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Synecta Product Sales: Sale of Synecta T1, T2, and Modular CDNP products for research use in cell therapy development. Products are sold directly through the company's website and via direct sales to cell therapy manufacturers and academic researchers.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
BlueWhale Bio product offering
Product offeringCore offering
BlueWhale Bio manufactures and sells the Synecta™ platform of cell-derived nanoparticles (CDNPs) used to activate and expand T cells during CAR-T and other immune cell therapy manufacturing. The CDNPs are engineered vesicles produced from mammalian cell lines that present defined combinations of activation signals, co-stimulatory ligands, membrane-bound cytokines, and adhesion molecules to mimic natural immune cell stimulation, eliminating bead-removal steps and enabling 3-day manufacturing with Day 0 lentiviral transduction. Customers are cell therapy developers, biomanufacturers, and academic medical centers, supported through direct sales, an e-commerce storefront, and a strategic GMP manufacturing partnership with Avantor.
Product overview
BlueWhale Bio offers the Synecta™ platform for cell therapy manufacturing, comprising cell-derived nanoparticle (CDNP) products for immune cell activation and expansion. The core products include Synecta™ T1 (contains activation signals, co-stimulatory ligands, and membrane-bound cytokines), Synecta™ T2 (flexible platform with cytokine addition freedom), and Synecta™ Modular (customizable CDNP development service). The platform is designed for CAR-T cell manufacturing workflows, enabling Day 0 lentiviral transduction and 3-day manufacturing processes. Regulatory support offerings include Drug Master File (DMF) for clinical trials and FDA Advanced Manufacturing Technology (AMT) designation. All products are for research use only.
Differentiator
Problem solved
Functional benefit
Brands
- Synecta™: Cell-derived nanoparticle (CDNP) platform for immune cell activation and expansion in cell therapy manufacturing
- Synecta™ T1
- Synecta™ T2
- Synecta™ Modular
Products and services
- Synecta™ T1 Cell-derived nanoparticles (CDNPs) for T cell activation and expansion in CAR-T manufacturing. Contains membrane-bound activation signal (OKT3 scFV), co-stimulatory ligands (CD86, 4-1BBL), and membrane-bound cytokines (IL-15RA/IL-15, IL-7) to mimic natural T-cell stimulation and enable activation without addition of soluble cytokines. Enables Day 0 lentiviral transduction, improved cell yields, and faster expansion for cell therapy developers and manufacturers.
- Synecta™ T2 Cell-derived nanoparticles for T cell activation and expansion providing maximal freedom to add cytokines. Contains OKT3 scFV activation signal and CD86 co-stimulatory ligand, designed for easy and robust activation with high dose-dependent cell yields. Requires no de-beading step and offers a simplified workflow for cell therapy developers and manufacturers.
- Synecta™ Modular Customizable CDNP development service that lets clients design cell-derived nanoparticles with specific transmembrane signals using BlueWhale Bio's modular cell line library. Enables Day 0 transduction, addition of any soluble or membrane-bound cytokines, and use with any bioreactor without protocol adjustments. Projects typically take 6-9 months with collaborative research planning for cell therapy developers seeking tailored activation reagents.
- Drug Master File (DMF) for Synecta T1 Regulatory support offering that allows clinical-stage cell therapy developers to reference BlueWhale Bio's FDA-accepted Drug Master File for Synecta T1 in their new or amended IND submissions, supporting use of Synecta T1 CDNPs in clinical CAR-T manufacturing without requiring customers to compile and submit their own manufacturing CMC filings.
- FDA Advanced Manufacturing Technology (AMT) Designation for Synecta Platform Regulatory designation service for the Synecta platform that signals FDA confidence in the scalability of the CDNP manufacturing approach, enables early FDA engagement on platform improvements, and supports customers pursuing commercial-scale cell therapy manufacturing.
Quantifiable outcome
- Up to 30% of samples fail to reach target dose due to suboptimal activation
- +2 more outcomes
Companies that use BlueWhale Bio
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
BlueWhale Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BlueWhale Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AvantorcoreStrategic partnership to accelerate CAR-T manufacturing by scaling up production of BlueWhale's Synecta CDNP platform. The collaboration aims to reduce manufacturing time and costs while expanding patient access. Avantor brings bioprocessing and GMP-grade custom ancillary-reagent manufacturing capabilities to produce GMP-grade CDNP materials.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
BlueWhale Bio competitors and assessment
Company assessmentDirect peers
- Miltenyi Biotec: Miltenyi Biotec is the dominant supplier of T-cell activation and expansion reagents (including T Cell TransAct nanomatrix) used in CAR-T manufacturing workflows globally. Direct competitor to BlueWhale's Synecta platform in the cell therapy activation reagent market.
- Bio-Techne: Bio-Techne supplies GMP-grade cytokines (IL-2, IL-7, IL-15) and activation reagents widely used in CAR-T and other cell therapy manufacturing. Competes with the soluble-cytokine-free value proposition of Synecta T1.
- CellGenix: CellGenix is a specialized supplier of GMP-manufactured raw materials and ancillary reagents for cell and gene therapy, including cytokines, media, and activation reagents. Closely comparable niche player focused on cell therapy manufacturing inputs.
Broad incumbents
- Thermo Fisher Scientific (Gibco CTS): Thermo Fisher's Gibco CTS product line includes Dynabeads CD3/CD28 activation reagents and a broad portfolio of cell therapy manufacturing consumables and instruments. A large incumbent whose cell therapy franchise directly overlaps with BlueWhale's target market.
- Cytiva: Cytiva (a Danaher company) supplies a broad portfolio of cell therapy bioprocessing tools, media, and instruments. Synergistic with BlueWhale's positioning - BlueWhale's lead investor Danaher also owns Cytiva - and represents both a partnership opportunity and a potential future competitive threat at the platform level.
- Lonza Cell & Gene Technologies: Lonza is one of the world's largest cell and gene therapy CDMOs and also supplies process development tools and ancillary materials. A broad incumbent in the cell therapy manufacturing value chain that competes for ancillary reagent spend with cell therapy developers.
- Charles River Laboratories: Charles River Laboratories operates a major cell and gene therapy CDMO business and supplies ancillary manufacturing materials. A scaled incumbent competing for the same customer wallet in cell therapy development and manufacturing services.
Emerging players
- MaxCyte: MaxCyte provides electroporation-based cell engineering technology used in cell therapy manufacturing, including partnerships with major CAR-T developers. Adjacent technology provider in the cell therapy manufacturing workflow that competes for similar customer relationships.
- Ori Biotech: Ori Biotech develops a fully closed, automated cell and gene therapy manufacturing platform. BlueWhale has co-hosted educational webinars with Ori, suggesting overlapping but not directly competing offerings in next-generation CAR-T manufacturing.
- Kytopen: Kytopen is an MIT spinout developing continuous flow electroporation technology for cell engineering, including CAR-T manufacturing. BlueWhale announced a partnership with Kytopen in September 2025, indicating complementary rather than directly competing technology positions.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BlueWhale Bio social profiles
Digital presenceBlueWhale Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
BlueWhale Bio leadership team
Management profileNumber of profiles
Profiles17 records
BlueWhale Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BlueWhale Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BlueWhale Bio
What does BlueWhale Bio do?
BlueWhale Bio manufactures and sells the Synecta™ platform of cell-derived nanoparticles (CDNPs) used to activate and expand T cells during CAR-T and other immune cell therapy manufacturing. The CDNPs are engineered vesicles produced from mammalian cell lines that present defined combinations of activation signals, co-stimulatory ligands, membrane-bound cytokines, and adhesion molecules to mimic natural immune cell stimulation, eliminating bead-removal steps and enabling 3-day manufacturing with Day 0 lentiviral transduction. Customers are cell therapy developers, biomanufacturers, and academic medical centers, supported through direct sales, an e-commerce storefront, and a strategic GMP manufacturing partnership with Avantor.
Is BlueWhale Bio a public or private company?
BlueWhale Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was BlueWhale Bio founded?
BlueWhale Bio was founded in 2023. It employs 11 to 50 people.
Where is BlueWhale Bio based?
BlueWhale Bio is headquartered in Philadelphia, United States, in the North America region.
How does BlueWhale Bio make money?
One revenue line is on record: synecta Product Sales.
Who are BlueWhale Bio's main competitors?
Direct peers on record are Miltenyi Biotec, Bio-Techne and CellGenix. Broad incumbents are Thermo Fisher Scientific (Gibco CTS), Cytiva, Lonza Cell & Gene Technologies and Charles River Laboratories. Emerging players are MaxCyte, Ori Biotech and Kytopen.
Does BlueWhale Bio have an API?
No public API is recorded for BlueWhale Bio.
What industry is BlueWhale Bio in?
BlueWhale Bio's product category is Cell Therapy Manufacturing Reagents. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 325414 and its SIC code is 2836.